89
Rating: Pace of capacity is crucial!
On the stock market, downgrades by analysts sometimes affect sentiment without changing the medical basis. How many additional production lines will come online and when, how quickly will waiting lists fall, and when will new reimbursement models take effect?
This question now needs to be answered. Nevertheless: If the available quantities increase visibly and the gross margin remains stable despite possible discounts, the Novo Nordisk share can pick up speed again. The roadmap is clearly defined for investors: approval and reimbursement decisions, capacity reports, regulation data. If these building blocks come together, student success creates a resilient earnings path – with prospects beyond the US market.
